Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Endocrinological Investigation"
DOI: 10.1007/s40618-021-01630-4
Abstract: Denosumab is a fully human monoclonal anti-RANK-L antibody that is clinically used to counteract the bone loss induced by exacerbated osteoclast activity. Indeed, its binding to RANK-L prevents the interaction RANK-L/receptor RANK that is essential… read more here.
Keywords: pediatric patients; acute hypercalcemia; interruption; mechanisms acute ... See more keywords